FDA’S ADVICE ON “NATURAL BODY

SOLUTION”

Dr. P.Naina Mohamed

Pharmacologist

INTRODUCTION On 05th May 2014, the Food and Drug

Administration (FDA) is advising consumers not to purchase or use “Natural Body

Solution”. “Natural Body Solution” is promoted and

sold for weight loss and sold on various websites and in some retail stores.

 FDA laboratory analysis confirmed that “Natural Body Solution” contains Sibutramine.

Sibutramine is a controlled substance and it was removed from the market in October 2010 for safety reasons. 

PO

SSIB

LE M

EC

HA

NIS

M

OF

AC

TIO

N

RIS

KS O

F N

ATU

RA

L

BO

DY

SO

LUTIO

N

CONTRAINDICATIONS OF NATURAL BODY SOLUTION

(SIBUTRAMINE) “Natural Body Solution” should not be used by the

patient who has … History of cerebrovascular disease (stroke or

transient ischemic attack) History of congestive heart failure History of coronary artery disease (eg, angina,

myocardial infarction) History of cardiac arrhythmias History of peripheral arterial occlusive disease Uncontrolled hypertension. Major eating disorders, major (eg, anorexia nervosa

or bulimia nervosa) Concomitant use with MAOIs Concomitant use with other centrally acting weight

loss drugs

SER

IOU

S D

RU

G

INTER

AC

TIO

NS

INTER

AC

TIO

N W

ITH

AN

TID

EP

RESSA

NTS

INTER

AC

TIO

N W

ITH

N

SA

IDS

INTER

AC

TIO

N W

ITH

D

EC

ON

GESTA

NTS

INTER

AC

TIO

N W

ITH

CY

P3A

4 IN

HIB

ITO

RS

FD

A

WA

RN

ING

S• FDA warns the Consumers should stop using this

product immediately and throw it away.  • FDA advises the Consumers who have

experienced any negative side effects should consult a health care professional as soon as possible. 

• FDA announces to the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals.  These products are typically promoted for sexual enhancement, weight loss, and body building, and are often represented as being “all natural.” 

• FDA claims that they are unable to test and identify all products marketed as dietary supplements on the market that have potentially harmful hidden ingredients. 

• FDA advises the Consumers to exercise caution before purchasing any product in the above categories. 

FDA

WA

RN

ING

S FDA has requested market withdrawal after reviewing

data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT).

SCOUT is part of a postmarket requirement to look at cardiovascular safety of sibutramine after the European approval of the drug. 

The trial demonstrated a 16 percent increase in the risk of serious heart events, including non-fatal heart attack, non-fatal stroke, the need to be resuscitated once the heart stopped, and death, in a group of patients given sibutramine compared with another given placebo.

There was a small difference in weight loss between the placebo group and the group that received sibutramine.

RECOMMENDATION: Physicians are advised to stop prescribing Sibutramine (Meridia) to their patients, and patients should stop taking this medication.

Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs.

http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm

REFE

REN

CES

http://www.fda.gov/Drugs/ResourcesF

orYou/Consumers/BuyingUsing

MedicineSafely/MedicationHealt

hFraud/ucm396061.htm?source

=govdelivery&utm_medium=e

mail&utm_source=govdelivery

http://www.micromedexsolutions.c

om CURRENT Diagnosis &

Treatment: Gastroenterology,

Hepatology, & Endoscopy,

2eNorton J. Greenberger, Richard

S. Blumberg, Robert Burakoff

Clinician's Pocket

Reference, 11eLeonard G. Gomella, Steven A.

Haist Harrison's Online

Featuring the complete

contents of Harrison's Principles

ofInternal Medicine, 18e

Basic & Clinical

Pharmacology, 12e

Bertram G. Katzung, Susan B.

Masters, Anthony J. Trevor

REFE

REN

CES

http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm

http://www.tga.gov.au/safety/alerts-medicine-sibutramine-101008.htm

http://www.medsafe.govt.nz/hot/media/2010/SibutramineOct2010.asp

http://www.bmj.com/content/340/bmj.c824